Infervision Closes D1 Round of Financing

On November 24, Infervision announced the completion of the D1 round of financing, led by Zhongguancun M&A Fund of Funds, with Zhongguancun Science City, Shenzhen Yicun Tongsheng, Shanghai Lianyi and old shareholders.

Infervision is committed to the clinical application of artificial intelligence and deep learning technologies in health care, providing AI-based platforms and tools fully integrated with medical workflows. Health providers in over 10 countries in Asia, Europe, North America use Infervision's highly precise and efficient clinical tools, empowering them with improved clinical insights. Infervision currently has 8 global offices and over 300 employees worldwide. Each day Infervision helps process over 55,000 exams, and accumulatively 19M case reviews since 2015.

As an innovative high-tech enterprise in artificial intelligence medical care, Infervision adheres to the belief of "using AI to build a community of human health and destiny" and uses deep learning technology to develop AI deployment management platforms, AI big data mining scientific research platforms, and AI clinical application platforms. Medical AI full-process platform, creating medical AI products such as medical quality control, health management, and scientific research innovation, effectively providing advanced and intelligent services to governments, medical institutions, doctors, and patients, and truly "AI improves life and health."

Just 1 day ago, it is assumed that the lung nodule AI product was approved by the National Food and Drug Administration (NMPA) Medical Device Class III certificate, becoming the only NMPA approved lung AI product. Inferred Medical has become the world's first AI medical company with complete four certificates in the four major medical markets of China NMPA, US FDA, Japan PMDA, and European CE.